Unknown

Dataset Information

0

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.


ABSTRACT: AIMS:The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment (AT-DILI). METHODS:We conducted a systematic review and performed a meta-analysis to clarify the role of NAT2 polymorphism in AT-DILI. PubMed, Medline and EMBASE databases were searched for studies published in English to December 31, 2017, on the association between the NAT2 polymorphism and AT-DILI risk. Outcomes were pooled with random-effects meta-analysis. Details were registered in the PROSPERO register (number: CRD42016051722). RESULTS:Thirty-seven studies involving 1527 cases and 7184 controls were included in this meta-analysis. The overall odds ratio (OR) of AT-DILI associated with NAT2 slow acetylator phenotype was 3.15 (95% CI 2.58-3.84, I2  = 51.3%, P = 0.000). The OR varied between different ethnic populations, ranging from 6.42 (95% CI 2.41-17.10, I2  = 2.3%) for the West Asian population to 2.32 (95% CI 0.58-9.24, I2  = 80.3%) for the European population. Within the slow NAT2 genotype, variation was also observed; NAT2*6/*7 was associated with the highest risk of AT-DILI (OR = 1.68, 95% CI 1.09-2.59) compared to the other slow NAT2 acetylators combined. CONCLUSIONS:NAT2 slow acetylation was observed to increase the risk of AT-DILI in tuberculosis patients. Our results support the hypothesis that the slow NAT2 genotype is a risk factor for AT-DILI.

SUBMITTER: Zhang M 

PROVIDER: S-EPMC6256008 | biostudies-other | 2018 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.

Zhang Min M   Wang Shuqiang S   Wilffert Bob B   Tong Rongsheng R   van Soolingen Dick D   van den Hof Susan S   Alffenaar Jan-Willem JW  

British journal of clinical pharmacology 20181003 12


<h4>Aims</h4>The aim of this study is to evaluate the potential association between N-acetyltransferase type 2 (NAT2) polymorphisms and drug-induced liver injury during anti-TB treatment (AT-DILI).<h4>Methods</h4>We conducted a systematic review and performed a meta-analysis to clarify the role of NAT2 polymorphism in AT-DILI. PubMed, Medline and EMBASE databases were searched for studies published in English to December 31, 2017, on the association between the NAT2 polymorphism and AT-DILI risk  ...[more]

Similar Datasets

| S-EPMC6234115 | biostudies-other
| S-EPMC4736635 | biostudies-literature
| S-EPMC4404341 | biostudies-literature
| S-EPMC7476276 | biostudies-literature
| S-EPMC7726956 | biostudies-literature
| S-EPMC3554644 | biostudies-other
| S-EPMC5997801 | biostudies-literature
| S-EPMC6385425 | biostudies-literature
| S-EPMC6134766 | biostudies-literature
| S-EPMC8343538 | biostudies-literature